Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: Possible usefulness of the domperidone test

Journal of Pediatric Endocrinology and Metabolism

Volumn 16, Issue 2, 2003, Pages 163-167

  Fideleff, Hugo L ^a   Azaretzky, Miriam ^b   Boquete, Hugo R ^a   Pujol, Andrea B ^a   Honfi, Margarita ^b   Suárez, Martha G ^a   Fideleff, Gabriel ^a   Giaccio, Ana V ^a  

^a Hospital General De Agudos Teodoro Alvarez   (Argentina)

^b Unidad Asistencial Dr César Milstein   (Argentina)

Author keywords

Adolescents; Domperidone; Hyperprolactinemia; Non tumoral hyperprolactinemia; Pituitary adenoma; Prolactinomas

Indexed keywords

DOMPERIDONE; PROLACTIN; THYROTROPIN; THYROXINE; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BODY WEIGHT; BREAST DEVELOPMENT; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; MALE; OLIGOMENORRHEA; PREPUBERTY; PROLACTIN BLOOD LEVEL; PUBERTY; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; ADENOMA; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; HYPOPHYSIS TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOGRAPHY; RADIOIMMUNOASSAY; SEXUAL DEVELOPMENT;

ADENOMA; ADOLESCENT; CHILD; DOMPERIDONE; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY NEOPLASMS; PROLACTIN; RADIOIMMUNOASSAY; SEX CHARACTERISTICS;

EID: 0042415498     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2003.16.2.163     Document Type: Article

References (16)

1. Pertzelan A, Bauman B, Gurewitz R, Matz S, Silbergeld A, Laron Z. Prolactin secreting pituitary adenoma in childhood and adolescence. Adv Biosci 1988; 69: 303-307.
2. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998; 83: 2777-2780.
3. Fideleff HL, Boquete HR, Sequera A, Suárez M, Sobrado P, Giaccio A. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 2000; 13: 261-267.
4. Flückiger E, Del Pozo E, Von Werder K. Prolactin: Physiology, Pharmacology and Clinical Findings. Berlín: Springer Verlag, 1982; 153.
5. L'Hermite M, Denayer P, Golstein J, Virasoro E, Vanhaelst L, Copinschi G, Robyn C. Acute endocrine profile of sulpiride in the human. Clin Endocrinol (Oxf) 1978; 9: 195-204.
6. Müller EE, Genazzani AR, Murru S. Nomifensine: diagnostic test in hyperprolactinemic states. J Clin Endocrinol Metab 1978; 47: 1352-1357.
7. Faglia G, Giovanelli MA, Beck-Peccoz P, Travaglini P, Ambrosi B, Spada A, Nissim M. Use of neuroactive drugs and hypothalamic regulatory hormones in the diagnosis of hyperprolactinemic states. In: Müller EE, ed. Neuroactive Drugs in Endocrinology: Physiologic, diagnostic and therapeutic Applications. Amsterdam: Elsevier/North-Holland, 1980; 263-278.
8. Webster J, Page MD, Bevan JS, Richards SH, Douglas-Jones AG, Scanlon MF. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests. Clin Endocrinol 1992; 36: 35-44.
9. Scanlon MF, Rodríguez-Arnao MD, McGregor AM, Weightman D, Lewis M, Cook DB, Gómez-Pan A, Hall R. Altered dopaminergic regulation of thyrotropin release in patients with prolactinomas: comparison with other tests of hypothalamic pituitary function. Clin Endocrinol 1981; 14: 133-143.
10. Arafah BM, Brodkey JS, Pearson OH. Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies. Metabolism 1986; 35: 905-912.
11. Scanlon MF, Peters JR, Salvador J, Richards SH, John R, Howell S, Williams ED, Thomas JP, Hall R. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and non-functional pituitary tumours: relationship to adenoma size at surgery. Clin Endocrinol 1986; 24: 435-446.
12. Prescott RWG, Johnston DG, Kendall Taylor P, Haigh J, Weightman DR, Hall K, Cook DB. The inability of dynamic tests of prolactin and TSH secretion to differentiate between tumorous and non-tumorous hyperprolactinemia. J Endocrinol Invest 1985; 8: 49-54.
13. Sawers HA, Robb OJ, Walmsley D, Strachan FM, Shaw J, Bevan JS. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinemia. Clin Endocrinol 1997; 46: 321-326.
14. Siegel S. Non Parametric Statistics for the Behavioral Sciences, 5th Ed. New York: McGraw-Book Company, 1990; 120-186.
15. Fideleff HL, Ruibal G, Boquete H, Pujol A, Sequera A, Sobrado P. Macroprolactinemia in childhood and adolescence: a cause of asymptomatic hyperprolactinemia. Horm Res 2000; 53: 16-19.
16. Howlett TA, Wass JA, Grossman A, Plowman PN, Charlesworth M, Touzel R, Rees LH, Savage MO, Besser GM. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol 1989; 30: 131-140.